Zentalis Pharmaceuticals, Inc. - ZNTL STOCK NEWS

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its Compensation Committee has granted stock options to one newly hired employee under its 2022 Employment Inducement Incentive Award Plan. The grant includes options to purchase 35,000 shares of common stock at an exercise price of $1.68 per share, matching the closing price on Nasdaq Global Market on the grant date.

The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement for individuals not previously employed by Zentalis.

Zentalis Pharmaceuticals (NASDAQ: ZNTL) has presented updated clinical data for azenosertib in treating Cyclin E1+ platinum-resistant ovarian cancer (PROC). The DENALI Part 1b study showed an Objective Response Rate (ORR) of approximately 35% in response-evaluable patients.

Key findings include a median duration of response of approximately 5.5 months, with patients continuing therapy. The safety profile remains well-characterized across over 350 patients treated at clinically active monotherapy doses, with no new safety concerns identified.

The company has aligned with FDA on the design of DENALI Part 2 study, expected to begin in 1H 2025, with topline data anticipated by year-end 2026. The study could potentially support accelerated approval, subject to FDA review. Notably, approximately 50% of PROC patients are Cyclin E1+, representing a substantial therapeutic and commercial opportunity.

Zentalis Pharmaceuticals (NASDAQ: ZNTL) announced a strategic restructuring to focus on late-stage development of its WEE1 inhibitor, azenosertib. The company plans a workforce reduction of approximately 40% to be completed in Q2 2025, extending its cash runway into late 2027.

The restructuring aims to support the execution of the potentially registration-enabling DENALI Part 2 study, with data readout anticipated by the end of 2026. The company will host a virtual corporate event on January 29, 2025, to present updated azenosertib clinical data and provide development and regulatory updates, including plans for registration-intent studies.

Zentalis Pharmaceuticals (ZNTL) announced that the FDA has granted Fast Track Designation to azenosertib for treating Cyclin E1-positive patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (PROC). This designation aims to expedite the development and review process for medicines addressing serious unmet medical needs.

The company published research in npj Precision Oncology demonstrating that high levels of Cyclin E1/CDK2 activation predict sensitivity to azenosertib. Zentalis will host a corporate webcast on January 29, 2025, to present comprehensive clinical data, including topline results from 102 patients in the Phase 2 DENALI study, final results from Phase 1b trial with 69 PROC patients, and data from 61 patients in the MAMMOTH trial. The event will also cover registration-intent study designs and regulatory updates.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its Compensation Committee has granted stock options to two newly hired employees on January 2, 2025. The grants include options to purchase 45,000 shares of common stock at an exercise price of $3.00 per share, matching the closing price on Nasdaq Global Market on the grant date.

The options were granted under the company's 2022 Employment Inducement Incentive Award Plan, following Nasdaq Listing Rule 5635(c)(4). These 10-year term options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.

Zentalis Pharmaceuticals (NASDAQ: ZNTL) has announced two key executive appointments to support its focus on developing azenosertib for gynecological malignancies. Wendy Chang joins as Chief People Officer, bringing over 20 years of biopharma experience, including previous roles at Harpoon Therapeutics, IDbyDNA, and Gilead Sciences. Haibo Wang has been appointed as Chief Business Officer, contributing more than 15 years of biopharma business development experience, notably managing Harpoon Therapeutics' recent acquisition by Merck in March 2024. Wang previously held positions at Hummingbird Bioscience and Amgen, where he was involved in significant acquisitions and collaborations.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced equity awards granted by its Compensation Committee on December 2, 2024. The grants include non-qualified stock options for: 3,028,800 shares to Julie Eastland (new CEO and President), 712,650 shares to Dr. Ingmar Bruns (new Chief Medical Officer), and 753,660 shares to five new employees. The options, granted under the 2022 Inducement Plan, have an exercise price of $3.66 per share. Eastland's options vest monthly over four years, while other employees' options vest 25% after one year and the remaining 75% monthly over three years, subject to continued service.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced key leadership changes to support registrational studies for its lead product candidate, azenosertib. Julie Eastland has been appointed CEO, President and Director, succeeding Kimberly Blackwell, who will remain as a strategic advisor. Ingmar Bruns has been named Chief Medical Officer, and Scott Myers joins as Board Chairperson. The company plans to host an investor event in January 2025 to share updated azenosertib clinical data and regulatory plans. Azenosertib has been administered to approximately 800 patients with various cancers, both as monotherapy and in combination treatments, showing potential as a novel treatment for gynecological cancers.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its Compensation Committee granted equity awards to three new employees on November 1, 2024. The grants include 79,500 non-qualified stock options at $3.32 per share and 21,000 restricted stock units under the 2022 Employment Inducement Incentive Award Plan. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over three years. The restricted stock units will vest in 25% increments annually over four years, subject to continued employment.